Aug 12, 2019 — 3 min read
Lunit has announced Korea MFDS (Ministry of Food and Drug Safety) approval of its AI solution for breast cancer, Lunit INSIGHT MMG. The medical software has been approved on July 29th, which marks a second approval of its AI solution by Korea MFDS since last year, when Lunit had gained initial regulatory clearance of its AI software.
Lunit INSIGHT MMG, which is now available for domestic sales in Korea, runs on Lunit’s proprietary AI technology, co-developed with prestigious Korean medical institutions--Yonsei Severance Hospital, Asan Medical Center, and Samsung Medical Center.
The software analyzes mammography images, with an indication of the location of lesions suspicious for breast cancer and an abnormality score of the detected lesion.
“Mammography is not easy to diagnose,” said Brandon Suh, CEO of Lunit. “Breast cancer is one of the most common female cancer, taking up to 24% of all female cancer cases. Among the patients suspicious of breast cancer after screening mammography, only 29% is actually diagnosed with cancer after biopsy.”
“With AI, we would like to increase the effectiveness of mammography screening and reduce unnecessary biopsies,” added Suh. “Lunit INSIGHT will improve the diagnosis accuracy of radiologists and decrease unnecessary recalls.”
According to the company, the algorithm is designed to assist prompt and accurate diagnosis of physicians, by showing only malignant lesion and automatically ignoring benign lesion. It has been trained with over 200,000 mammography cases, which includes 50,000 breast cancer cases.
“High false positive rate has been a major problem of CAD (Computer Aided Detection) software,” said Hyo-Eun Kim, Head of Breast Radiology at Lunit. “To overcome this problem, our software has been developed to distinguish benign and malignant lesion with high accuracy. The MFDS clinical trials had shown that Lunit INSIGHT MMG can significantly improve the diagnostic accuracy of radiologists.”
Lunit provides an online demo (https://insight.lunit.io) for users to test the performance of its software. “Anyone can try using our algorithm through this website,” said Minhong Jang, CBO of Lunit. “With Lunit INSIGHT MMG, breast cancer can be diagnosed earlier. It will also reduce the burden of patients due to unnecessary additional tests.”
The company had previously received MFDS clearance last year in August for its AI solution for chest x-ray. The software is currently being used at multiple hospitals and medical examination centers throughout the country, including Seoul National University Hospital.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?